Trials / Completed
CompletedNCT02987777
Prognostic Impact of Programmed Death Ligand-1 Expression in Advanced Endometrial Cancer
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 80 (actual)
- Sponsor
- Institut de Cancérologie de Lorraine · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study was to assess the frequency of PD-L1 expression in stage III-IV ECs and to investigate its correlation impact with progression-free survival (PFS), and clinicopathological features including microsatellite instability and quantified stromal and intraepithelial tumor-infiltrating CD8+ lymphocytes (TILs)
Conditions
Timeline
- Start date
- 2016-01-01
- Primary completion
- 2016-08-01
- Completion
- 2016-08-01
- First posted
- 2016-12-09
- Last updated
- 2016-12-09
Source: ClinicalTrials.gov record NCT02987777. Inclusion in this directory is not an endorsement.